首页 | 本学科首页   官方微博 | 高级检索  
     


SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling
Authors:Chuan Xu  Guoxiang Jin  Hong Wu  Wei Cui  Yu-Hui Wang  Rajesh Kumar Manne  Guihua Wang  Weina Zhang  Xian Zhang  Fei Han  Zhen Cai  Bo-Syong Pan  Che-Chia Hsu  Yiqiang Liu  Anmei Zhang  Jie Long  Hongbo Zou  Shuang Wang  Xiaodan Ma  Jinling Duan  Bin Wang  Weihui Liu  Haitao Lan  Qing Xiong  Gang Xue  Zhongzhu Chen  Zhigang Xu  Mark E. Furth  Sarah Haigh Molina  Yong Lu  Dan Xie  Xiu-Wu Bian  Hui-Kuan Lin
Abstract:Cancer stem-like cells (CSLCs) acquire enhanced immune checkpoint responses to evade immune cell killing and promote tumor progression. Here we showed that signal regulatory protein γ (SIRPγ) determined CSLC properties and immune evasiveness in a small population of lung adenocarcinoma (LUAD) cancer cells. A SIRPγhi population displayed CSLC properties and transmitted the immune escape signal through sustaining CD47 expression in both SIRPγhi and SIRPγlo/– tumor cells. SIRPγ bridged MST1 and PP2A to facilitate MST1 dephosphorylation, resulting in Hippo/YAP activation and leading to cytokine release by CSLCs, which stimulated CD47 expression in LUAD cells and consequently inhibited tumor cell phagocytosis. SIRPγ promoted tumor growth and metastasis in vivo through YAP signaling. Notably, SIRPγ targeting with genetic SIRPγ knockdown or a SIRPγ-neutralizing antibody inhibited CSLC phenotypes and elicited phagocytosis that suppressed tumor growth in vivo. SIRPG was upregulated in human LUAD and its overexpression predicted poor survival outcome. Thus, SIRPγhi cells serve as CSLCs and tumor immune checkpoint–initiating cells, propagating the immune escape signal to the entire cancer cell population. Our study identifies Hippo/YAP signaling as the first mechanism by which SIRPγ is engaged and reveals that targeting SIRPγ represents an immune- and CSLC-targeting strategy for lung cancer therapy.
Keywords:Immunology
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号